TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, v...

por Demarchi, Martin, Coliat, Pierre, Mclendon, Kristi, Chung Shii Hii, Jocelyn, Feyaerts, Peggy, Ang, Felicia, Jaison, Litha, Deforce, Filip, Derde, Marie Paule, Kim, Michael Jinwoo, Park, Lisa Soyeon, Detappe, Alexandre, Pivot, Xavier
Publicado 2021

Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting

por Pivot, Xavier, Manikhas, Alexey Georgievitch, Shamrai, Volodymyr, Dzagnidze, Giorgi, Soo Hoo, Hwoei Fen, Kaewkangsadan, Viriya, Petrelli, Fausto, Villanueva, Cristian, Kim, Jamie, Pradhan, Sumita, Jaison, Litha, Feyaerts, Peggy, Kaufman, Leonard, Derde, Marie-Paule, Deforce, Filip, Cox, David G.
Publicado 2023

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab

por Demarchi, Martin, Coliat, Pierre, Barthelemy, Philippe, Schott, Roland, BenAbdelghani, Meher, Kim, Michael, Hii, Jocelyn Chung Shii, Feyaerts, Peggy, Ang, Felicia Rui Xia, Derde, Marie Paule, Deforce, Filip, Petit, Thierry, Schwabe, Chris, Wynne, Chris, Park, Lisa Soyeon, Pivot, Xavier
Publicado 2021

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial

por Pivot, Xavier, Georgievich, M. A., Shamrai, Volodymyr, Dzagnidze, Giorgi, Soo Hoo, Hwoei Fen, Kaewkangsadan, Viriya, Petrelli, Fausto, Villanueva, Cristian, Nikolaevich, Lipatov O., Hii, Jocelyn, Kim, Jamie, Pradhan, Sumita, Jaison, Litha, Feyaerts, Peggy, Kaufman, Leonard, Derde, Marie-Paule, Bonamy, Ghislain M. C., Deforce, Filip, Cox, David G.
Publicado 2022